NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Alto Marketing Ltd
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Successful £2.4m Funding Round Takes ScreenTape Pioneer to the Next Level - Lab901 have announced major new equity funding of £2.4m
Successful £2.4m Funding Round Takes ScreenTape Pioneer to the Next Level

 

NewswireToday - /newswire/ - Southampton, Hampshire, United Kingdom, 2009/09/14 - Lab901 have announced major new equity funding of £2.4m.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Lab901 Limited, the Edinburgh-based developer and manufacturer of innovative automation systems for the life science industry, has successfully raised £2.4 million in equity funding. This latest vote of confidence comes from Lab901’s strong consortium of UK investors, comprising Archangel Informal Investment Ltd, Alliance Trust Equity Partners (ATEP), Scottish Enterprise SVF, Foresight 3 VCT plc and TriCapital Ltd.

Lab901 (lab901.com) will use the cash injection to expand international sales of its ScreenTape® laboratory analysis platform and further develop its product range. This automated platform replaces manual analysis of bio-molecules (Proteins, DNA and RNA), giving faster results and enabling better decision making. It is now widely used for infectious disease testing, (e.g. screening for swine flu), in the molecular diagnostics market where it continues to deliver proven commercial benefits. Since launching in 2007, ScreenTape is now sold in more than 20 countries – including S. Korea, S. Africa, Canada, Venezuela , Malaysia and Mexico as well as many European countries – through a network of 16 distribution partners.

Building on this success, Lab901 also recently launched two new versions of ScreenTape for Protein and RNA analysis, targeting the significant global market for Biomedical research in Pharmaceutical Companies, Universities and Research Institutes. These products are currently being sold direct throughout Europe, with global roll-out commencing 2010.

Commenting on the latest round of funding, Joel Fearnley, CEO and co-founder of Lab901, said: “Lab901 has an enviable track record with the successful development and commercialisation of the innovative ScreenTape platform and our existing investors have provided the finance we need to support planned global sales growth.”

John Waddell, CEO of Archangel Informal Investments, added: “In challenging times, it is very encouraging that Archangel investors are continuing to support Scottish companies like Lab901 to help them grow into global businesses. This funding round reflects the dedication of the management team in meeting key milestones and its proven ability to succeed on the global stage.”

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Successful £2.4m Funding Round Takes ScreenTape Pioneer to the Next Level

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 davidr[.]alto-marketing.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)